CRISPR Therapeutics AG Earnings Call Transcripts
Fiscal Year 2026
-
The company is rapidly expanding its pipeline beyond Casgevy, with six programs set for near-term data and a focus on cardiovascular, autoimmune, and oncology franchises. Innovations in gene editing, delivery, and siRNA are driving new therapies, while strong financials support broad R&D investment.
-
The session highlighted a strategic shift toward disease-focused franchises in cardiovascular and autoimmune areas, with robust pipeline progress expected by 2027. Casgevy momentum continues, while in vivo, siRNA, and cell therapy programs advance, supported by strong early data and upcoming clinical milestones.
-
Zugo-cel, an allogeneic CAR-T with advanced edits, is advancing in both oncology and autoimmune indications, showing strong early efficacy and broad applicability. Regulatory and commercialization strategies focus on parallel development, competitive pricing, and global access, while in vivo CAR-T platforms are being engineered for future expansion.
-
Multiple franchises are advancing with strong commercial and clinical momentum, including Casgevy’s global rollout, best-in-class in vivo gene editing, and promising CAR-T and cardiovascular programs. Key data readouts and regulatory clarity in 2026 are expected to drive the next phase of growth.
Fiscal Year 2025
-
Significant progress across the portfolio includes strong CASGEVY launch, promising CTX310 and Factor XI data, and upcoming cell therapy updates. Differentiation in gene editing safety and lipid management, plus strategic positioning in competitive markets, support a positive outlook.
-
A diversified pipeline in cardiovascular, autoimmune, oncology, and diabetes is advancing, with key clinical readouts expected in the next year. CASGEVY's launch is progressing well, supported by strong demand and expanding site productivity. Regulatory and partnership strategies are evolving, with major data and policy developments anticipated in the coming months.
-
CASGEVY's launch is progressing well, with expansion into multiple therapeutic areas and a strong cash position supporting strategic growth. Durable, one-time therapies in cardiovascular and other indications are prioritized, with siRNA and gene editing platforms advancing toward key clinical milestones.
-
Major franchises in cardiovascular and autoimmune diseases are advancing, with best-in-class gene editing data for ANGPTL3 and expanding indications for allogeneic CAR-Ts. CASGEVY's global rollout is accelerating, and new modalities and partnerships are being pursued.
-
A robust gene-editing pipeline is advancing across four franchises, with Casgevy's global launch driving revenue and new partnerships expanding technology reach. 2025 is set as a pivotal year with multiple clinical readouts and a strong balance sheet supporting sustainable growth.
-
A diversified gene-based medicine pipeline is advancing, highlighted by strong Casgevy launch metrics, a strategic Sirius siRNA partnership, and best-in-class early data for CTX310. Multiple clinical readouts and business development activities are expected to drive value over the next 12–18 months.
-
Minimal tariff exposure and strong federal support position the platform well amid sector headwinds. Casgevy's launch is progressing as planned, with global expansion and non-genotoxic conditioning poised to boost growth. Multiple data readouts in 2024 will define the future pipeline.
-
Gene editing is advancing rapidly, with commercial therapies now available and strong pharma interest. Casgevy's launch is expanding globally, especially in the Middle East, while the pipeline targets major unmet needs in cardiovascular, oncology, and diabetes. Continued clinical progress supports ambitions for significant long-term growth.
-
A diverse pipeline is advancing, including commercialized gene therapies, allogeneic CAR-T, and cardiovascular programs. Profitability is targeted by 2028, with key mid-year updates expected for oncology, autoimmune, and cardiovascular assets.
-
CASGEVY's global launch marks a new era in gene-editing therapies, with strong system support and a robust pipeline spanning oncology, cardiovascular, and diabetes. Allogeneic CAR-Ts show high efficacy and safety, while in vivo programs advance durable gene editing for major diseases.
Fiscal Year 2024
-
The discussion highlighted strong global demand and expansion plans for CASGEVY, ongoing investment in gene editing and CAR-T platforms, and a robust pipeline targeting rare, common, and autoimmune diseases. Key data updates in cardiovascular, oncology, and autoimmune programs are expected within the next year.
-
A broad pipeline includes the first approved CRISPR medicine, advanced CAR T therapies, and in vivo gene editing for cardiovascular and autoimmune diseases. Exponential growth in CASGEVY's launch, strong safety/efficacy for CTX112, and multiple data readouts are expected in the next year.
-
The pipeline is prioritized for maximum impact across rare and common diseases, with strong innovation in gene editing, delivery, and manufacturing. Casgevy's launch is driving global growth, while new platforms in cardiovascular, autoimmune, oncology, and regenerative medicine are advancing rapidly.
-
The company highlighted strong clinical and commercial progress with Casgevy, expanding global access and pipeline breadth. In vivo gene editing programs are advancing rapidly, with initial data expected this year, and CAR T and regenerative medicine platforms are poised for further innovation.